| Net Loss Per Share |
NOTE 5. NET LOSS PER SHARE
The following table presents the computation of basic and diluted net loss per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
June 30, |
|
|
Six Months Ended
June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
Numerator |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(23,296 |
) |
|
$ |
(3,253 |
) |
|
$ |
(46,259 |
) |
|
$ |
(25,382 |
) |
Denominator |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average common shares outstanding |
|
|
36,848,602 |
|
|
|
36,084,113 |
|
|
|
36,718,994 |
|
|
|
35,783,067 |
|
Less: Weighted-average shares subject to repurchase |
|
|
— |
|
|
|
(598 |
) |
|
|
— |
|
|
|
(301 |
) |
Denominator for basic and diluted net loss per share attributable to common stockholders |
|
|
36,848,602 |
|
|
|
36,083,515 |
|
|
|
36,718,994 |
|
|
|
35,782,766 |
|
Basic and diluted net loss per share |
|
$ |
(0.63 |
) |
|
$ |
(0.09 |
) |
|
$ |
(1.26 |
) |
|
$ |
(0.71 |
) |
The Company reported net losses for all periods presented and, as such, all potentially dilutive shares of common stock would have been antidilutive for such periods. The table below presents the weighted-average securities (in common equivalent shares) outstanding during the periods presented that have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
June 30, |
|
|
Six Months Ended
June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
Common stock options, restricted stock units and performance stock units |
|
|
10,949,114 |
|
|
|
10,266,921 |
|
|
|
10,850,896 |
|
|
|
10,143,835 |
|
Warrants to purchase common stock |
|
|
496,612 |
|
|
|
496,612 |
|
|
|
496,612 |
|
|
|
496,612 |
|
Common stock issuable in connection with convertible senior notes |
|
|
3,842,961 |
|
|
|
5,475,369 |
|
|
|
3,842,961 |
|
|
|
5,475,369 |
|
|
|
|
15,288,687 |
|
|
|
16,238,902 |
|
|
|
15,190,469 |
|
|
|
16,115,816 |
|
|